Alkermes plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends

SG&A Expense Trends: Alkermes plc vs Amphastar Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial for investors and stakeholders. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Alkermes plc and Amphastar Pharmaceuticals, Inc., from 2014 to 2023.

Alkermes plc has shown a significant upward trend in SG&A expenses, increasing by approximately 245% over the decade. This growth reflects the company's strategic investments in marketing and administrative capabilities. In contrast, Amphastar Pharmaceuticals, Inc. experienced a more modest increase of around 99% in the same period, indicating a more conservative approach to operational spending.

The data reveals that Alkermes consistently outspends Amphastar, with 2023 figures showing Alkermes' expenses nearly 8.6 times higher. These insights provide a window into each company's operational strategies and market positioning, offering valuable information for potential investors.